Abstract
High-dose chemotherapy followed by autologous peripheral-blood stem cell transplantation has resulted in long-term disease-free survival of 30%-60% in selected patients with refractory and relapsed Hodgkin's disease. In addition, a significant reduction in early transplant-related mortality in more recent studies has led to the widespread acceptance of autografting. Comparatively few studies of allografting for Hodgkin's disease have been performed. Although no prospective randomized trials have been performed, historical results show a significantly lower relapse rate when allografting results are compared to autografting results. These results suggest that a graft-versus-Hodgkin's disease effect may exist. Unfortunately, the lower relapse rate following allografting is offset by higher transplant-related mortality. The use of low-intensity nonmyeloablative regimens for allografting may harness a graft-versus-Hodgkin's disease effect with less morbidity and mortality than that observed following conventional allografting.
| Original language | English |
|---|---|
| Pages (from-to) | 212-221 |
| Number of pages | 10 |
| Journal | Clinical Lymphoma |
| Volume | 2 |
| Issue number | 4 |
| Publication status | Published - 2002 |
Fingerprint
Keywords
- Allogeneic transplants
- Autologous stem cell transplantation
- Hodgkin's disease
- Relapsed disease
ASJC Scopus subject areas
- Cancer Research
Cite this
Stem cell transplantation for Hodgkin's disease : A review of the literature. / Carella, Angelo M.
In: Clinical Lymphoma, Vol. 2, No. 4, 2002, p. 212-221.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stem cell transplantation for Hodgkin's disease
T2 - A review of the literature
AU - Carella, Angelo M.
PY - 2002
Y1 - 2002
N2 - High-dose chemotherapy followed by autologous peripheral-blood stem cell transplantation has resulted in long-term disease-free survival of 30%-60% in selected patients with refractory and relapsed Hodgkin's disease. In addition, a significant reduction in early transplant-related mortality in more recent studies has led to the widespread acceptance of autografting. Comparatively few studies of allografting for Hodgkin's disease have been performed. Although no prospective randomized trials have been performed, historical results show a significantly lower relapse rate when allografting results are compared to autografting results. These results suggest that a graft-versus-Hodgkin's disease effect may exist. Unfortunately, the lower relapse rate following allografting is offset by higher transplant-related mortality. The use of low-intensity nonmyeloablative regimens for allografting may harness a graft-versus-Hodgkin's disease effect with less morbidity and mortality than that observed following conventional allografting.
AB - High-dose chemotherapy followed by autologous peripheral-blood stem cell transplantation has resulted in long-term disease-free survival of 30%-60% in selected patients with refractory and relapsed Hodgkin's disease. In addition, a significant reduction in early transplant-related mortality in more recent studies has led to the widespread acceptance of autografting. Comparatively few studies of allografting for Hodgkin's disease have been performed. Although no prospective randomized trials have been performed, historical results show a significantly lower relapse rate when allografting results are compared to autografting results. These results suggest that a graft-versus-Hodgkin's disease effect may exist. Unfortunately, the lower relapse rate following allografting is offset by higher transplant-related mortality. The use of low-intensity nonmyeloablative regimens for allografting may harness a graft-versus-Hodgkin's disease effect with less morbidity and mortality than that observed following conventional allografting.
KW - Allogeneic transplants
KW - Autologous stem cell transplantation
KW - Hodgkin's disease
KW - Relapsed disease
UR - http://www.scopus.com/inward/record.url?scp=0036225309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036225309&partnerID=8YFLogxK
M3 - Article
VL - 2
SP - 212
EP - 221
JO - Clinical Lymphoma
JF - Clinical Lymphoma
SN - 1526-9655
IS - 4
ER -